TuHURA Biosciences Inc (NASDAQ:HURA), a Florida-based Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta Inc (OTC Pink:KANT), a Washington-based clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced on Tuesday that TuHURA stockholders approved all of the proposals set forth at the company's Special Meeting of Stockholders held on 23 June 2025.

The proposals included an increase of the company's authorised shares to 200 million shares, and a proposal to reincorporate the company in Delaware.

Additionally, Kineta stockholders approved the proposed merger with TuHURA at Kineta's Special Meeting of Stockholders held on 23 June 2025. The parties anticipate that the merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.